Owkin
Owkin Expands Into Western Europe With Nine Precision Medicine Partnerships
The firm will employ its machine learning-enabled diagnostic and drug discovery tools in nine centers across Germany, Austria, and Switzerland.
The firm has early results from more than 400 cancer samples suggesting the multimodal profiles could aid clinical decision-making and drug target discovery.
With $50M Investment in MOSAIC Project, Owkin Seeks to Become Cancer 'Drug Discovery Enterprise'
Premium
The MOSAIC research coalition brings together Owkin, NanoString, and European and US institutions to create a massive spatial omics dataset in pursuit of novel cancer biomarkers
Owkin, NanoString Technologies Launch $50M Spatial Omics Research Program for Cancer Research
The companies have assembled a coalition of research institutions in the US and Europe to apply spatial omics to biomarker and drug discovery.
Owkin, Stanford Medicine Collaborate on AI-Driven Lung Cancer, Mesothelioma Biomarker Discovery
The French bioinformatics firm will analyze molecular and other multimodal data in search of new cancer therapeutics.
Aug 21, 2020